Tricida, Inc.

OTCPK:TCDA.Q 株式レポート

時価総額：US$580.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Tricida 将来の成長

Future 基準チェック /06

現在、 Tricidaの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

57.3%

収益成長率

58.11%

EPS成長率

Pharmaceuticals 収益成長14.9%
収益成長率n/a
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日29 Mar 2023

今後の成長に関する最新情報

Recent updates

Seeking Alpha • Oct 19

Tricida enters $125M debt facility

Tricida (NASDAQ:TCDA) gets into a debt facility of $125M with Hercules Capital, provider of customized debt financing for companies in the life sciences and technology-related markets. Of the $125M, $100M will be available for drawdown at Tricida’s option subject to the achievement of certain milestones. Under the terms of the debt facility, $25M will be available for drawdown until December 31, 2022, subject to the announcement of positive data from the VALOR-CKD trial.  An additional $25M will be available for drawdown until the earlier of ten business days following the filing of the NDA for veverimer and September 15, 2023. An additional $50M will be available for drawdown until the earlier of ten business days following the FDA approval of veverimer and February 15, 2024. The loans bear interest at a floating per annum interest rate equal to the greater of either 8.75% or the lesser of 8.75% plus the prime rate as reported in The Wall Street Journal minus 6.25% and 10.25%.
Seeking Alpha • Sep 21

Tricida: Important Binary Event Coming Up

Summary TCDA has a major binary event next month. Data from VALOR may turn out well given the logic behind early trial termination, prior data and so on. There could be some quick upside in the next 30 odd days. Tricida (TCDA) has been doing wonderfully lately, over the last 12 months, but it is down considerably from its PDUFA highs. That was from two years ago, when I used to cover the stock. I recall buying some TCDA, making good money, and then losing some money on the shares I held on to, because their lead asset veverimer was handed a CRL. The stock is up these days not because the CRL was resolved, but because of a number of other small and large things. Let's first discuss the CRL, though. Then we will see what has been responsible for the stock’s sudden buoyancy. Veverimer is targeting metabolic acidosis in CKD or chronic kidney disease patients. In an earlier trial, after 12 weeks of treatment, TRC101 or veverimer was able to increase blood bicarbonate level of at least 4 milliequivalents per liter (mEq/L) or achieved a blood bicarbonate level in the normal range of 22 to 29 mEq/L in 59.2% patients, compared with 22.5% of them in the placebo group (p< 0.0001). However, one of veverimer’s major problem is the standardly used therapy for this indication, which you can buy in a bottle from a grocery store for a few bucks. This is bicarbonate of soda, and while there have been no industry-sponsored trials for obvious reasons, it has long been used by doctors to treat metabolic acidosis. Its problem is that too much sodium content in the blood can cause heart diseases, which is where veverimer has a great deal of utility with its completely different mechanism of action. However, the FDA was not convinced, and it issued a CRL, asking for, among other things: Additional data regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate. Whether the demonstrated effect size would be reasonably likely to predict clinical benefit. I discussed all this in an earlier article from two years ago. A summary of the CRL from the company management was here: “According to the CRL, the FDA is seeking additional data beyond the TRCA-301 and TRCA-301E trials regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate and the applicability of the treatment effect to the U.S. population. FDA also expressed concern as to whether the demonstrated effect size would be reasonably likely to predict clinical benefit,” Tricida said. This was an accelerated approval, and the company was already conducting VALOR-CKD at that time as a confirmatory trial. After the CRL, they said that interim data from this trial could be used to provide the data required by the FDA. This trial was supposed to enroll ~1500 patients and topline in 2023-24. In May, the company did an “administrative stop” to this trial after enrolling 1480 patients last year, and after 237 patients reached a primary endpoint event — end-stage renal disease, renal death, or greater than or equal to 40% reduction in eGFR or estimated glomerular filtration rate — in the renal outcomes study. This was done to conserve their cash reserve, which will be near depleted this quarter. Moreover, the FDA seems to have agreed that this may work. As Phil Nadeau at Cowen explained: Assuming a true hazard ratio ((HR)) of 0.70, the trial would be 78% powered at 250 events. Switching from power to observed HR, VALOR-CKD could be successful at 250 events if the observed HR is 0.78. There is only a modest increase to 0.79 observed HR should 300 events be in the final analysis. This calculation on the observed HR required for significance is based on 300 simulations on trial outcomes.
分析記事 • Sep 14

Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)

Today we will run through one way of estimating the intrinsic value of Tricida, Inc. ( NASDAQ:TCDA ) by estimating the...
分析記事 • Dec 14

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

Investors who take an interest in Tricida, Inc. ( NASDAQ:TCDA ) should definitely note that the CFO & Executive VP...

業績と収益の成長予測

OTCPK:TCDA.Q - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2023N/A-58-29-291
12/31/2022N/A-109-89-891
9/30/2022N/A-134-109-109N/A
6/30/2022N/A-148-119-119N/A
3/31/2022N/A-153-136-135N/A
12/31/2021N/A-177-140-140N/A
9/30/2021N/A-181-145-144N/A
6/30/2021N/A-219-177-176N/A
3/31/2021N/A-244-212-211N/A
12/31/2020N/A-265-233-231N/A
9/30/2020N/A-268-220-219N/A
6/30/2020N/A-235-202-201N/A
3/31/2020N/A-213-158-157N/A
12/31/2019N/A-177-131-130N/A
9/30/2019N/A-146-134-133N/A
6/30/2019N/A-131-119-118N/A
3/31/2019N/A-120-104-104N/A
12/31/2018N/A-103-96-95N/A
9/30/2018N/A-96-79-78N/A
6/30/2018N/A-77-60-58N/A
3/31/2018N/A-60-49-47N/A
12/31/2017N/A-41-41-40N/A

アナリストによる今後の成長予測

収入対貯蓄率: TCDA.Q今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TCDA.Q今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TCDA.Q今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TCDA.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: TCDA.Q来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TCDA.Qの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2023/06/13 07:03
終値2023/06/13 00:00
収益2022/09/30
年間収益2021/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Tricida, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3

アナリスト機関
Dana FlandersGoldman Sachs
Jessica FyeJ.P. Morgan
Philip NadeauTD Cowen